Vivo Opportunity, LLC's Form 4 filing
InMed Pharmaceuticals Inc. (INM) · filed Jul 16, 2026
- Accession no.
- 0001213900-26-078891
- Filed
- Jul 16, 2026, 9:58 PM ET
- Trade date
- Jul 14-16, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. Open-market purchases total $31.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vivo Opportunity, LLCCIK 0001728970 | 10% Owner |
| Vivo Opportunity Cayman Fund, L.P.CIK 0001875722 | 10% Owner |
| Vivo Opportunity Cayman, LLCCIK 0001930113 | 10% Owner |
| Vivo Opportunity Fund Holdings, L.P.CIK 0001930214 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | Common Shares | PPurchaseAcquired | +4,882 | $1.55 | +$7,567.1 | 729,277 | Indirect | |
| Jul 14, 2026 | Common Shares | PPurchaseAcquired | +493 | $1.55 | +$764.15 | 73,628 | Indirect | |
| Jul 15, 2026 | Common Shares | PPurchaseAcquired | +13,761 | $1.55 | +$21,329.55 | 743,038 | Indirect | |
| Jul 15, 2026 | Common Shares | PPurchaseAcquired | +1,389 | $1.55 | +$2,152.95 | 75,017 | Indirect | |
| Jul 16, 2026 | Common Shares | PPurchaseAcquired | +19 | $1.55 | +$29.45 | 743,057 | Indirect | |
| Jul 16, 2026 | Common Shares | PPurchaseAcquired | +2 | $1.55 | +$3.1 | 75,019 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.